Data-Driven and Structure-Based Modelling for the Discovery of Human DNMT1 Inhibitors: A Pathway to Structure–Activity Relationships
Source abstract
Abstract
Nowadays, the explosive growth of knowledge in the epigenetics field has highlighted DNA methyltransferase 1 (DNMT1) as a key regulator of genomic methylation patterns and a promising therapeutic target in several diseases. In light of the increasing clinical interest in epigenetic enzymes, the present study aimed to develop a robust computational framework for the discovery of novel DNMT1 inhibitors, merging both structure and data-driven strategies. Particularly, the study compiled a dataset of established DNMT1 inhibitors and calculated a series of molecular properties, thus enabling the training of a machine learning model to capture critical structure–activity relationships (SARs). When benchmarked against known active compounds, the model effectively discriminated between putative inhibitors and non-inhibitors with high accuracy. In parallel, molecular docking was conducted to screen additional uncharacterized compounds, estimating their binding affinity to human DNMT1. Their respective properties were then extracted and fed into the aforementioned model to predict their inhibitory potential. Our comparative evaluation against known human DNMT1 inhibitors demonstrated high predictive accuracy, confirming the reliability of the proposed integrated approach. By uniting molecular docking with data-driven SAR modelling, this workflow offers an expedited fast-track avenue for identifying promising human DNMT1 inhibitors while reducing experimental overhead. The results highlight the effectiveness of combining cheminformatics, machine learning, and in silico techniques to guide rational drug design, and accelerate the discovery of novel epigenetic inhibitors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Epigenetics and DNA Methylation · Machine Learning in Bioinformatics · Genomics and Rare Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Chemistry, Analysis & Design of Food Processes, Department of Food Science and Technology, University of West Attica, Agiou Spyridonos 28, 12243 Egaleo, Greece
Department of Biomedical Engineering, University of West Attica, Agiou Spyridonos 28, 12243 Egaleo, Greece
Institute of Chemical Biology, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece
General Hospital of Veria, 59132 Veria, Greece
References (47)
Show source-provided references
1. Perceptions of Epigenetics10.1038/nature05913 ↗
2. DNA Methylation: Mega-Year Inheritance with the Help of Darwin10.1016/j.cub.2020.02.034 ↗
3. Epigenetic Regulation of Early Human Embryo Development10.1016/j.stem.2023.09.010 ↗
4. How Epigenetics Impacts on Human Diseases10.1016/j.ejim.2023.05.036 ↗
5. Davletgildeeva, A.T., and Kuznetsov, N.A. (2024). The Role of DNMT Methyltransferases and TET Dioxygenases in the Maintenance of the DNA Methylation Level. Biomolecules, 14.10.3390/biom14091117 ↗
6. Linde, J., and Zimmer-Bensch, G. (2020). DNA Methylation-Dependent Dysregulation of GABAergic Interneuron Functionality in Neuropsychiatric Diseases. Front. Neurosci., 14.10.3389/fnins.2020.586133 ↗
7. Changes in DNMT1 Expression as a Marker of Epigenetic Regulation Disturbanses in Multiple Sclerosis Patients10.17816/MAJ623679 ↗
8. Molecular Epigenetic Dynamics in Breast Carcinogenesis10.1007/s12272-021-01348-0 ↗
9. Selective Non-Nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells10.1021/jm4012627 ↗
10. Non-Nucleoside Inhibitors of DNMT1 and DNMT3 for Targeted Cancer Therapy10.1016/j.phrs.2024.107328 ↗
11. Epigenetics-Targeted Drugs: Current Paradigms and Future Challenges10.1038/s41392-024-02039-0 ↗
12. Exposome: Epigenetics and Autoimmune Diseases10.1016/j.autrev.2024.103584 ↗
13. Epigenetics of Human Diseases and Scope in Future Therapeutics
14. Lu, W., Zhang, R., Jiang, H., Zhang, H., and Luo, C. (2018). Computer-Aided Drug Design in Epigenetics. Front. Chem., 6.10.3389/fchem.2018.00057 ↗
15. In Silico Structure-Activity-Relationship (SAR) Models from Machine Learning: A Review10.1002/ddr.20410 ↗
16. Structure-Based Molecular Modeling in SAR Analysis and Lead Optimization10.1016/j.csbj.2021.02.018 ↗
17. Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators10.2174/1386207320666170130144443 ↗
18. Machine-Learning Methods for Ligand–Protein Molecular Docking10.1016/j.drudis.2021.09.007 ↗
19. Boczar, D., and Michalska, K. (2024). A Review of Machine Learning and QSAR/QSPR Predictions for Complexes of Organic Molecules with Cyclodextrins. Molecules, 29.10.3390/molecules29133159 ↗
20. A Review of Deep Learning Methods for Ligand Based Drug Virtual Screening10.1016/j.fmre.2024.02.011 ↗
21. Liu, X., Jiang, S., Duan, X., Vasan, A., Liu, C., Tien, C., Ma, H., Brettin, T., Xia, F., and Foster, I.T. (2024). Binding Affinity Prediction: From Conventional to Machine Learning-Based Approaches. arXiv.
22. Bragina, M.E., Daina, A., Perez, M.A.S., Michielin, O., and Zoete, V. (2022). The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience. Int. J. Mol. Sci., 23.10.3390/ijms23020811 ↗
23. SAR around (l)-S-Adenosyl-l-Homocysteine, an Inhibitor of Human DNA Methyltransferase (DNMT) Enzymes10.1016/j.bmcl.2009.03.113 ↗
24. Webina: An Open-Source Library and Web App That Runs AutoDock Vina Entirely in the Web Browser10.1093/bioinformatics/btaa579 ↗
25. ADMETlab 2.0: An Integrated Online Platform for Accurate and Comprehensive Predictions of ADMET Properties10.1093/nar/gkab255 ↗
26. Ladika, G., Christodoulou, P., Kritsi, E., Tsiaka, T., Sotiroudis, G., Cavouras, D., and Sinanoglou, V.J. (2025). Exploring Postharvest Metabolic Shifts and NOX2 Inhibitory Potential in Strawberry Fruits and Leaves via Untargeted LC-MS/MS and Chemometric Analysis. Metabolites, 15.10.3390/metabo15050321 ↗
27. A Computational Approach for the Discovery of Novel DNA Methyltransferase Inhibitors10.3390/cimb46040213 ↗
28. Mechanisms for the Inhibition of DNA Methyltransferases by Tea Catechins and Bioflavonoids10.1124/mol.104.008367 ↗
29. Zsidó, B.Z., and Hetényi, C. (2020). Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome. Int. J. Mol. Sci., 21.10.3390/ijms21114134 ↗
30. Crystal Structure of Human DNA Methyltransferase 110.1016/j.jmb.2015.06.001 ↗
31. Tea Polyphenol (−)-Epigallocatechin-3-Gallate Inhibits DNA Methyltransferase and Reactivates Methylation-Silenced Genes in Cancer Cell Lines
32. Discovery and Development of DNA Methyltransferase Inhibitors Using in Silico Approaches10.1016/j.drudis.2014.12.007 ↗
33. DNA Methyltransferase and Its Clinical Applications10.1088/1755-1315/512/1/012082 ↗
34. Kaveh, S., Mani-Varnosfaderani, A., and Neiband, M.S. (2024). Deriving General Structure–Activity/Selectivity Relationship Patterns for Different Subfamilies of Cyclin-Dependent Kinase Inhibitors Using Machine Learning Methods. Sci. Rep., 14.10.1038/s41598-024-66173-z ↗
35. Molecular Descriptors, Structure Generation, and Inverse QSAR/QSPR Based on SELFIES10.1021/acsomega.3c01332 ↗
36. DNA Methylation Inhibitors: Retrospective and Perspective View10.1016/bs.acr.2021.03.007 ↗
37. Identification of a Novel Quinoline-Based DNA Demethylating Compound Highly Potent in Cancer Cells10.1186/s13148-019-0663-8 ↗
38. Descriptors and Their Selection Methods in QSAR Analysis: Paradigm for Drug Design10.1016/j.drudis.2016.06.013 ↗
39. A Systematic Method for Selecting Molecular Descriptors as Features When Training Models for Predicting Physiochemical Properties10.1016/j.fuel.2022.123836 ↗
40. An Automated Framework for QSAR Model Building10.1186/s13321-017-0256-5 ↗
41. Open-Source Platform to Benchmark Fingerprints for Ligand-Based Virtual Screening10.1186/1758-2946-5-26 ↗
42. Feature Selection Methods in QSAR Studies10.5740/jaoacint.SGE_Goodarzi ↗
43. Prado-Romero, D.L., Saldívar-González, F.I., López-Mata, I., Laurel-García, P.A., Durán-Vargas, A., García-Hernández, E., Sánchez-Cruz, N., and Medina-Franco, J.L. (2024). De Novo Design of Inhibitors of DNA Methyltransferase 1: A Critical Comparison of Ligand- and Structure-Based Approaches. Biomolecules, 14.10.26434/chemrxiv-2024-m8q63 ↗
44. Saldívar-González, F.I., Gómez-García, A., Chávez-Ponce de León, D.E., Sánchez-Cruz, N., Ruiz-Rios, J., Pilón-Jiménez, B.A., and Medina-Franco, J.L. (2018). Inhibitors of DNA Methyltransferases From Natural Sources: A Computational Perspective. Front. Pharmacol., 9.10.3389/fphar.2018.01144 ↗
45. QSAR-Driven Rational Design of Novel DNA Methyltransferase 1 Inhibitors
46. Epigenetic Target Profiler: A Web Server to Predict Epigenetic Targets of Small Molecules10.1021/acs.jcim.1c00045 ↗
47. Zhang, Z., Wang, G., Li, Y., Lei, D., Xiang, J., Ouyang, L., Wang, Y., and Yang, J. (2022). Recent Progress in DNA Methyltransferase Inhibitors as Anticancer Agents. Front. Pharmacol., 13.10.3389/fphar.2022.1072651 ↗